Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Non-canonical NFκB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NFκB pathway.

Oncogene - 1 Mar 2017

Roy P, Mukherjee T, Chatterjee B, Vijayaragavan B, Banoth B, Basak S

Abstract excerpt

Environmental drug resistance constitutes a serious impediment for therapeutic intervention in multiple myeloma. Tumor-promoting cytokines, such as tumor necrosis factor (TNF), induce nuclear factor-κB (NFκB)- driven expression of pro-survival factors, which confer resistance in myeloma cells to apoptotic insults from TNF-related apoptosis-inducing ligand (TRAIL) and other chemotherapeutic drugs. It is thought...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Cell Survival
Share to Enzyme Activation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Multiple Myeloma

Share to NF-kappa B

Share to TNF-Related Apoptosis-Inducing Ligand

Share to Tumor Necrosis Factor-alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 27641334
DOI: 10.1038/onc.2016.309
PMCID: PMC5346295

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-canonical NFκB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NFκB pathway.PMID 27641334Read ↗

WITHDRAWN: Canonical NF-κB regulator CYLD mutations reinforce RelB mediated disease pathogenesis in Multiple MyelomaSemantic proximity Read ↗

NF-kappaB in the pathogenesis and treatment of multiple myeloma.Semantic proximity Read ↗

Frequent Engagement of RelB Activation Is Critical for Cell Survival in Multiple MyelomaSemantic proximity Read ↗

Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple MyelomaSemantic proximity Read ↗

Overcoming bortezomib resistance in multiple myelomaSemantic proximity Read ↗

Multiple myeloma: lusting for NF-kappaB.Semantic proximity Read ↗

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.Semantic proximity Read ↗

Radiation-triggered Tumor Necrosis Factor (TNF) α-NFκB Cross-signaling Favors Survival Advantage in Human Neuroblastoma CellsSemantic proximity Read ↗

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.Semantic proximity Read ↗

Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.Semantic proximity Read ↗

Structural and biological features of the TNF receptor and TNF ligand superfamilies: Interactive signals in the pathobiology of Hodgkin's diseaseSemantic proximity Read ↗

N4BP1 is dimerization-dependent linear ubiquitin reader regulating TNFR1 signalling through linear ubiquitin binding and Caspase-8-mediated processingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.